Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Bolt Biotherapeutics (BOLT) Equity Average (2020 - 2025)

Bolt Biotherapeutics' Equity Average history spans 6 years, with the latest figure at $35.5 million for Q3 2025.

  • For Q3 2025, Equity Average fell 55.07% year-over-year to $35.5 million; the TTM value through Sep 2025 reached $35.5 million, down 55.07%, while the annual FY2024 figure was $85.0 million, 40.21% down from the prior year.
  • Equity Average for Q3 2025 was $35.5 million at Bolt Biotherapeutics, down from $42.8 million in the prior quarter.
  • Across five years, Equity Average topped out at $299.6 million in Q2 2021 and bottomed at $35.5 million in Q3 2025.
  • The 5-year median for Equity Average is $135.2 million (2023), against an average of $148.9 million.
  • The largest annual shift saw Equity Average skyrocketed 602.36% in 2021 before it tumbled 55.07% in 2025.
  • A 5-year view of Equity Average shows it stood at $262.5 million in 2021, then plummeted by 31.44% to $180.0 million in 2022, then plummeted by 33.05% to $120.5 million in 2023, then tumbled by 46.38% to $64.6 million in 2024, then tumbled by 45.1% to $35.5 million in 2025.
  • Per Business Quant, the three most recent readings for BOLT's Equity Average are $35.5 million (Q3 2025), $42.8 million (Q2 2025), and $52.0 million (Q1 2025).